Loading clinical trials...
Loading clinical trials...
Safety and Efficacy Assessment of Geltim LP® 1 mg/g (Unpreserved Timolol Gel - TG1030) in Ocular Hypertensive or Glaucomatous Patients Stabilized by Xalatan® With Ocular Intolerance Signs.
Conditions
Interventions
Geltim LP 1 mg/g
Xalatan
Locations
1
France
Clermont-Ferrand, France
Start Date
July 1, 2008
Primary Completion Date
July 1, 2009
Completion Date
December 1, 2009
Last Updated
April 4, 2017
NCT04354545
NCT07298356
NCT07396441
NCT06979752
NCT07390890
NCT07145073
Lead Sponsor
Laboratoires Thea
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions